Article Write-Up

The goal of each write-up was to professional explain an article written about the specifc company. The client must be able to undertsand the gist of the article in the write-up and have no further questions on something that was included. Some include brief notes to send to leadership which also has to be concise and ready to send. Inlcuding only the necessary information along with professional language was extremely important.

Hi all,

The twelvenote team wanted to flag a piece published by NASDAQ.com (UVM: 2,447,047), titled “Albireo Pharma (NASDAQ:ALBO) Is Using Debt Safely.” The piece, written by a contributor for Simply Wall St., assesses the risk in investing in Albireo given its debt. It concludes that while there is risk, multiple factors also show promising upsides to investing in Albireo Pharma, such as the company’s “dazzling” revenue growth.

The writer suggests that Albireo is using debt in a way that appears to be both “safe and conservative.” It notes that Albireo does not have a heavy debt load, and predicts the company is unlikely to face trouble with lenders given it has “plenty” of assets.

It also notes that Albireo has managed to grow its revenue by 421%, to US $45M in the last year, describing the trend as “virtually a hole-in-one of revenue growth.” The piece states that though loss-making companies are generally risker to invest in, Albireo’s promising revenue growth is “good news” for shareholders as it seems likely Albireo may increase its free cash flow in the years to come. The writer then advises readers to keep an eye on Albireo’s long-term profit and revenue trend.

We’ve attached the full text of the piece for your reference. If you have any questions, please let us know.

Best,

[XX]

Article Write-Up

Hi all,

As a follow up to our earlier flag, the twelvenote team wanted to flag another piece on NASDAQ.com (UVM:2M) titled, “Has Albireo Pharma (ALBO) Outpaced Other Medical Stocks This Year?”

The piece – stemming from Zacks Equity Research’s “Zacks Ranks” – highlights that the Albireo stock is outperforming compared to other companies within the Medical sector. The article notes that in the last 90 days Albireo’s full-year earnings has moved 8.1% higher and has returned 2.9% this year while other stocks in the group have lost about 13.2% on average. The article mentions this shows analyst sentiment is stronger and the stock’s outlook is improving.

This article was also syndicated indicated by Yahoo! Finance (UVM: 32M). We’ve attached the full text of the article for your reference.

We’ve also drafted a note for you to share the two articles with the leadership team sharing the positive analyst opinions ahead of the upcoming earnings call.

If you have any questions, please let us know.

Best,

[XX]

Article Write-Up

Hi all,

The twelvenote team wanted to flag an article published in ZS, a business consulting company, titled “US emerging pharma and biotech first launches: A story of over- and underperformance.” The article provides an analysis of the performance of emerging pharmaceutical and biotech companies and understand which launches succeeded and the factors that impacted performance. The article compares actual launch-year sales to pre-launch forecasts and categorized the organizations into three groups (met expectations, overperformed, underperformed).

The analysis also included Albireo and of 30 emerging pharma first launches, Albireo was among four companies that met expectations with the launch of Bylvay in 2021. While the article does not mention Albireo in text, the attached image shows Albireo’s success among other biotech companies. Inferring from the article discussion, a significant factor that supported Albireo’s performance was the novelty of the drug in a new indication.

As you prepare for the upcoming earnings call, we believed that this article would be relevant to share with you. We’ve also drafted a quick update below for you to share with the leadership team.

On another note, we wanted to share a study published in Clinical and Experimental Gastroenterology, titled “Functional, Diagnostic and Therapeutic Aspects of Bile.” The study lead, Monjur Ahmed, Thomas Jefferson University Hospital, analyzed the role of bile acids and specific treatments to be used for bile related issues, and mentions the FDA approval of Bylvay the first treatment for pruritus in patients.

We’ve attached the full text of both articles for your reference. If you have any questions, please let us know.

Best,
[XX]

Hi all,

As we work towards our upcoming earnings call, I wanted to share an article that I felt was relevant published in in ZS, a business consulting company, titled “US emerging pharma and biotech first launches: A story of over- and underperformance.” The article provides an analysis of the performance of emerging pharmaceutical and biotech companies and found that Albireo was four of 30 companies that met expectations with the Bylvay launch! Per the discussion in the article, a significant contributor to our success in meeting expectations is the novelty of the product focusing on a new indication.

Please see attached the full text of the article (note: does not mention Albireo in the text) and the image highlighting the launch performances of the companies on the expectation meter.

Please let me know of any questions.

Thanks,

[XX]

Article Write-Up

Hi all,

The twelvenote team wanted to flag a press release from CANbridge Pharmaceuticals sharing that the first patient has been dosed in the Phase 2 EMBARK study of maralixibat in biliary atresia in Peking, China.

The clinical trial is evaluating the efficacy and safety of maralixibat in the treatment of patients with biliary atresia after Kasai surgery and is expected to enroll up to 20 patients in China and 72 patients globally. The release notes that CANbridge and Mirum Pharmaceuticals have an exclusive license agreement for the development, commercialization, and manufacture, under certain conditions, of maralixibat and that the drug can be commercialized for Alagille syndrome, PFIC, and biliary atresia in Greater China.

Mirum did not issue their own press release, and this release received minimal coverage. If you have any questions, please let us know.

Best,

[XX]

Article Write-Up

Hi all,

The twelvenote team wanted to flag MirumPharma.com’s curtain raiser release regarding the data the company plans to present at the upcoming EASL and ESPGHAN conferences in June.

The release states Mirum has eight abstracts along with three oral presentations, presenting new data from their clinical studies about maralixibat associated with improved quality of life as well as results from a multi-national survey of patient-reported data assessing pruritus and disease burden in adults with primary sclerosing cholangitis.

It also states Mirum will host a scientific symposium at each meeting: during EASL, the company will present on the roles of the patient, caregiver, and physician in adult and pediatric cholestasis management whereas at ESPGHAN, Mirum will discuss the management of cholestatic disease in children.

All abstracts can be accessed via the Journal of Paediatric Gastroenterology and Nutrition. If you have any questions, please let us know.

Best,

[XX]

​

The writer suggests that Albireo is using debt in a way that appears to be both “safe and conservative.” It notes that Albireo does not have a heavy debt load, and predicts the company is unlikely to face trouble with lenders given it has “plenty” of assets.

​

​

Article Write-Up

If you have any questions, please let us know.

Article Write-Up

As you prepare for the upcoming earnings call, we believed that this article would be relevant to share with you. We’ve also drafted a quick update below for you to share with the leadership team.

Article Write-Up

Article Write-Up